close

For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Named Technology Group of the Year by Law360
  • Ranked #1 in the Americas for number of technology deals in 2015 by Mergermarket
  • Nearly 20 percent of Fenwick partners are ranked by Chambers
  • Consistently ranked among the top 10 law firms in the U.S. for diversity
  • Recognized as having top mentoring and pro bono programs by Euromoney

MORE >

We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041
650.988.8500

San Francisco Office
555 California Street
13th Floor
San Francisco, CA 94104
415.875.2300

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101
206.389.4510

New York Office
1211 Avenue of the Americas
32nd Floor
New York, NY 10036
212.921.2001

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200


Federal Circuit Issues En Banc Decision in Marine Polymer

Should intervening rights apply to claims that were not textually amended during a reexamination proceeding but were effectively narrowed by the patentee's arguments? Following a controversial panel decision last September in Marine Polymer Technologies, Inc. v. Hemcon, Inc. that expanded intervening rights for reexamination, an en banc Federal Circuit on March 15 ruled that intervening rights only apply if claim language is substantively amended or new claims are added. In a closely divided 6-4 ruling, the court specifically rejected the original panel’s determination that intervening rights can arise as a result of the patentee's statements to the U.S. Patent and Trademark Office ("PTO") during reexamination that effectively limit the claim but do not result in an amendment to the claim language.

Marine Polymer sued HemCon, alleging that HemCon infringed certain claims of U.S. Patent No. 6,864,245 (the '245 patent), which claims a biocompatible polymer p-GlcNAc that accelerates hemostasis and is useful in trauma units for treating serious wounds. A central issue during the district court's claim construction proceedings, which would ultimately be the focus of the appeal, was the interpretation of the term "biocompatible" in an asserted independent claim of the '245 patent. The district court construed the term to mean "polymers... with low variability, high purity, and no detectable biological reactivity as determined by biocompatibility tests" (emphasis added). Applying this construction, the district court granted summary judgment of literal infringement of all seven asserted claims, relying on expert evidence that biocompatibility tests of HemCon's accused products had shown "no detectable biological reactivity." At trial, the jury upheld the validity of the '245 patent and found that Marine Polymer was entitled to a reasonable royalty of approximately 88% of HemCon's profits. The district court entered final judgment in September 2010, granting reasonable royalty damages for the past infringement in the amount of $29,410,246 and issuing a permanent injunction barring future infringement of the asserted claims of the '245 patent.

During the district court proceedings, HemCon requested reexamination of the '245 patent. In reexamination, the examiner initially adopted a different claim construction than the district court, finding that "biocompatible" meant "low variability, high purity, and little or no detectable reactivity" (emphasis added). The examiner argued that the court's construction was inconsistent with several dependent claims of the '245 patent that required biocompatibility test result scores of zero, one, or two on a five-point scale. Applying this broader construction, the examiner issued a preliminary rejection of all the claims of the '245 patent as invalid in light of the prior art. In response, Marine Polymer argued for an adoption of the district court's interpretation of the term "biocompatible," and it cancelled the six original dependent claims that had specifically required a test score of one or two (i.e., that required at least some reactivity). The examiner approved the claims as amended, and in March 2011, the PTO issued a reexamination certificate cancelling dependent claims 4, 5, 13, 14, 21, and 22.

Following the issuance of the reexamination certificate, HemCon appealed the district court's final judgment to the Federal Circuit, arguing that the scope of the claims of the '245 patent had been substantively narrowed during reexamination and that it was therefore entitled to absolute and equitable intervening rights under 35 U.S.C. §§ 252 and 307, which provide an accused infringer the right to use or sell specific products made, used, or purchased before the grant of the reexamined patent. In a 2-1 decision by the three-judge panel in September 2011, the majority agreed with HemCon, finding that intervening rights should apply in light of Marine Polymer's arguments to the PTO during reexamination, which it argued had substantively narrowed the construction of "biocompatibility" even though the language of the asserted independent claim had not ultimately changed.

The panel majority reasoned that if a patentee is able through argument to preserve the validity of its patent over prior art during reexamination by narrowing the scope of the claims, those same arguments should give rise to intervening rights even if the actual language of the claims is not amended. In a dissenting opinion, Judge Lourie argued that under the plain language of the relevant statute, 35 U.S.C. § 307(b), an amendment or claim addition was a threshold requirement for considering whether claim scope has changed for purposes of an intervening rights analysis.

On January 20, 2012, the full Federal Circuit decided to hear this case en banc and ordered that the original panel decision be vacated and the appeal reinstated. In a March 15, 2012 en banc decision, a 6-4 majority of the full Court held that the rule of reexamination intervening rights articulated in the earlier panel decision was wrong. Citing the "plain and unambiguous" statutory language of 35 U.S.C. § 307(b), the Court held that regardless of any arguments made by the patentee during reexamination, intervening rights will not apply unless the reexamination resulted in a textual change to the language of the claims. The dissent, conceding that "not every argument during reexamination should give rise to intervening rights," argued that intervening rights should be available at least where "an argument during reexamination rises to the level of a clear and unambiguous disclaimer or disavowal of the original, correct claim construction."

The Federal Circuit's decision to reject the panel's ruling in favor of the status quo will come as a relief to patent owners, who will be free to argue against asserted rejections of their claims during reexamination without risking their right to collect past damages for infringement. The fact that a patentee's statements to the PTO can result in a change of the claim meaning for purposes of prosecution history estoppel, but cannot on their own give rise to intervening rights, is an inconsistency that remains unresolved.


For further information, please contact:

Heather N. Mewes, Partner, Litigation Group
hmewes@fenwick.com, 415.875.2302

Rajiv P. Patel, Partner, Intellectual Property Group
rpatel@fenwick.com, 650.335.7607

Betsy White, Associate, Litigation Group
bwhite@fenwick.com, 650.335.7931

©2012 Fenwick & West LLP. All Rights Reserved.

The views expressed in this publication are solely those of the author, and do not necessarily reflect the views of Fenwick & West LLP or its clients. The content of the publication ("content") is not offered as legal should not be regarded as advertising, solicitation, legal advice or any other advice on any particular matter. The publication of any content is not intended to create and does not constitute an attorney-client relationship between you and Fenwick & West LLP. You should not act or refrain from acting on the basis of any content included in the publication without seeking the appropriate legal or professional advice on the particular facts and circumstances at issue.